133 related articles for article (PubMed ID: 1173103)
1. Secondary hyperparathyroidism. Conservative management in patients with renal insufficiency.
Popovtzer MM; Pinggera WF; Robinette JB
JAMA; 1975 Mar; 231(9):960-2. PubMed ID: 1173103
[TBL] [Abstract][Full Text] [Related]
2. Uremic osteodystrophy. The therapeutic consequences of effective control of serum phosphorus.
Pinggera WF; Popovtzer MM
JAMA; 1972 Dec; 222(13):1640-2. PubMed ID: 4678366
[No Abstract] [Full Text] [Related]
3. Secondary hyperparathyroidism in severe chronic renal failure is corrected by very-low dietary phosphate intake and calcium carbonate supplementation.
Barsotti G; Cupisti A; Morelli E; Meola M; Cozza V; Barsotti M; Giovannetti S
Nephron; 1998; 79(2):137-41. PubMed ID: 9647491
[TBL] [Abstract][Full Text] [Related]
4. [Outcome of osseous lesions of hyperparathyroidism in a patient with chronic renal failure treated with high doses of vitamin D].
Verberckmoes R; Tanghe W; Michielsen P; Vandenbroucke J
J Urol Nephrol (Paris); 1970 Sep; 76(9):790-7. PubMed ID: 5482082
[No Abstract] [Full Text] [Related]
5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
6. [Methods of correcting hyperphosphatemia in chronic renal failure and in dialysis (review)].
Novikov AI
Ter Arkh; 1997; 69(12):63-7. PubMed ID: 9503540
[No Abstract] [Full Text] [Related]
7. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
[TBL] [Abstract][Full Text] [Related]
8. Plasma parathormone, calcium and phosphorus in patients with renal osteodystrophy undergoing chronic hemodialysis.
Genuth SM; Sherwood LM; Vertes V; Leonards JR
J Clin Endocrinol Metab; 1970 Jan; 30(1):138-40. PubMed ID: 5409532
[No Abstract] [Full Text] [Related]
9. Vitamin D metabolism during recovery from severe osteitis fibrosa cystica of primary hyperparathyroidism.
Gonzalez-Villapando C; Porath A; Berelowitz M; Marshall L; Favus MJ
J Clin Endocrinol Metab; 1980 Nov; 51(5):1180-3. PubMed ID: 6893459
[TBL] [Abstract][Full Text] [Related]
10. Successful medical management of osteitis fibrosa due to "tertiary" hyperparathyroidism.
Vosik WM; Anderson CF; Steffee WP; Johnson WJ; Arnaud CD; Goldsmith RS
Mayo Clin Proc; 1972 Feb; 47(2):110-3. PubMed ID: 5010725
[No Abstract] [Full Text] [Related]
11. The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease.
Slatopolsky E; Bricker NS
Kidney Int; 1973 Aug; 4(2):141-5. PubMed ID: 4355426
[No Abstract] [Full Text] [Related]
12. Calcium and phosphorus metabolism in chronic uremia.
Fiaschi E; Mioni G; Maschio G; D'Angelo A; Ossi E
Nephron; 1975; 14(2):163-80. PubMed ID: 1093055
[TBL] [Abstract][Full Text] [Related]
13. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure.
Andress DL; Norris KC; Coburn JW; Slatopolsky EA; Sherrard DJ
N Engl J Med; 1989 Aug; 321(5):274-9. PubMed ID: 2631697
[TBL] [Abstract][Full Text] [Related]
14. Alphacalcidol oral pulses are effective in secondary hyperparathyroidism prior to dialysis.
Koskimies O; Ala-Houhala M
Clin Nephrol; 1996 Jul; 46(1):70-1. PubMed ID: 8832157
[TBL] [Abstract][Full Text] [Related]
15. Is anemia of chronic renal failure related to secondary hyperparathyroidism?
Podjarny E; Rathaus M; Korzets Z; Blum M; Zevin D; Bernheim J
Arch Intern Med; 1981 Mar; 141(4):453-5. PubMed ID: 7212887
[TBL] [Abstract][Full Text] [Related]
16. Management of bone disease in the dialysis patient.
Crooks PW; Coburn JW
Blood Purif; 1985; 3(1-3):27-41. PubMed ID: 3913448
[TBL] [Abstract][Full Text] [Related]
17. [Disorders of Ca metabolism in chronic renal insufficiency].
Ritz E; Sieberth HG; Krempien B
Klin Wochenschr; 1971 Dec; 49(24):1305-14. PubMed ID: 4944934
[No Abstract] [Full Text] [Related]
18. Marked direct suppression of primary hyperparathyroidism with osteitis fibrosa cystica by intravenous administration of 1,25-dihydroxycholecalciferol.
Patron P; Gardin JP; Borensztein P; Prigent A; Paillard M
Miner Electrolyte Metab; 1989; 15(6):321-5. PubMed ID: 2615719
[TBL] [Abstract][Full Text] [Related]
19. Non-suppressible secondary hyperparathyroidism in chronic progressive renal disease.
Slatopolsky E; Rutherford WE; Hoffsten PE; Elkan IO; Butcher HR; Bricker NS
Kidney Int; 1972; 1(1):38-46. PubMed ID: 5075944
[No Abstract] [Full Text] [Related]
20. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ
Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
